11/6
08:05 am
otlk
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
Low
Report
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
10/18
11:53 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $50.00 price target on the stock.
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $50.00 price target on the stock.
10/17
09:00 am
otlk
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment
Low
Report
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment
10/11
09:00 pm
otlk
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
9/16
08:05 am
otlk
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
Medium
Report
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
9/13
09:13 am
otlk
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series [Yahoo! Finance]
Medium
Report
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series [Yahoo! Finance]
9/13
09:05 am
otlk
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
Medium
Report
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
9/4
08:35 am
otlk
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
Medium
Report
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
9/3
08:45 am
otlk
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
High
Report
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
9/3
08:04 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target lowered by analysts at Ascendiant Capital Markets from $35.00 to $33.00. They now have a "buy" rating on the stock.
High
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target lowered by analysts at Ascendiant Capital Markets from $35.00 to $33.00. They now have a "buy" rating on the stock.
8/26
07:40 am
otlk
Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles [Seeking Alpha]
High
Report
Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles [Seeking Alpha]